Greg Rotz

Greg Rotz

New York

Greg Rotz is an advisor to executives in the Health industry for Strategy&, PwC’s strategy consulting business. Based in New York, he is a Principal with PwC US. He focuses on serving life science clients and works with senior business leaders in the sector to grow the value of their companies by addressing major strategy, organization, and execution issues.

Greg’s key areas of expertise are:

  • Enterprise value management
  • Strategic management
  • Organic growth
  • Commercial effectiveness

Greg has applied this expertise to help his clients make a meaningful impact on their company’s performance and capabilities. Examples of high-profile engagements include:

  • Helping the CEO of a major global pharmaceutical company go from 4th quartile to 1st quartile performance
  • Supporting the President and CEO of a U.S. pharmaceutical operation to establish and manage the unit’s new strategic agenda for winning
  • Creating a new organic growth plan for a U.S. diagnostics business, including new product and service offers, re-design of sales structure and practices, and investment in high-growth segments
  • Developing and launching a truly novel business model for a prescription drug product, working in an integrated fashion with nearly every function in the company (marketing, sales, legal, supply chain, finance, government relations, etc.)
  • Working with the management team of a U.S. nutrition company to create new customer insights and ideas for improving profitable growth (market share and margin gains).

Prior joining Strategy&, Greg was a Partner with boutique management consultancy Marakon. In addition to significant client service responsibilities, Greg served in various leadership positions at Marakon including: Managing Partner for North America, leader of the Strategy Execution practice, co-leader of the pharmaceuticals industry team, and various recruiting roles.

Greg has published a number of articles on the management challenges facing today’s pharmaceutical executives. In addition, he has served as an expert for various press articles and conferences (e.g., Wharton Healthcare Conference).

Greg holds a B.A. in public policy and economics from The College of William and Mary. Outside of the office, Greg’s interests include American history and politics, Yankees baseball, and enjoying New York City with his wife.

 

Authored articles

  • 2017 Pharmaceuticals and Life Sciences Trends

    Turn the corner

    In short, as pharma companies shift their investments and focus, they will have to come up with their own approaches for innovation, patient engagement, data, and proof of value. Some companies may be hesitant to change what has worked in the past. But the shifts roiling the healthcare industry are inevitably creating an entirely new commercial landscape for all the organizations involved in the sector. Pharma companies are a critical part of this ecosystem. The way they opt to address its challenges will affect not only their future but the future direction of patient care, provider decisions, and payment mechanisms.

    Also contributing to this article was Rick Edmunds.

  • Fit for Growth in medtech
  • Pharmaceuticals: Go to Market More Effectively
  • Total Shareholder Returns
  • Getting Big by Going Small